Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen on Pace for Largest Percent Increase Since November 2020 -- Data Talk

12/06/2021 | 01:19pm EST

Amgen Inc. (AMGN) is currently at $208.58, up $6.14 or 3.03%

-- Would be highest close since Nov. 12, 2021, when it closed at $211.39

-- On pace for largest percent increase since Nov. 4, 2020, when it rose 4.67%

-- Currently up five of the past six days

-- Currently up four consecutive days; up 4.88% over this period

-- Longest winning streak since Aug. 17, 2021, when it rose for six straight trading days

-- Best four day stretch since the four days ending Nov. 3, 2021, when it rose 5.29%

-- Down 9.28% year-to-date; on pace for worst year since 2016, when it fell 9.93%

-- Down 20.07% from its all-time closing high of $260.95 on July 20, 2020

-- Down 7.89% from 52 weeks ago (Dec. 7, 2020), when it closed at $226.45

-- Down 19.51% from its 52-week closing high of $259.14 on April 20, 2021

-- Up 4.88% from its 52-week closing low of $198.88 on Nov. 30, 2021

-- Traded as high as $211.79; highest intraday level since Nov. 12, 2021, when it hit $212.88

-- Up 4.62% at today's intraday high; largest intraday percent increase since Jan. 28, 2021, when it rose as much as 10.21%

-- Contributed 40.47 points to the DJIA so far today

All data as of 12:57:35 PM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

12-06-21 1318ET

All news about AMGEN INC.
01/20AMGEN PLUGS IN : Electric Vehicle Pilot Program Advances Carbon Neutrality Goal
01/20Amgen Secures Japanese Approval of Non-Small Cell Lung Cancer Drug Lumakras
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
01/19FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid T..
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
01/13Amgen, AstraZeneca's Asthma Drug Tezspire Available For Shipment to US Wholesalers
01/13BridgeBio Pharma, Inc. Announces Clinical Collaboration with Amgen Inc. to Study BBP-39..
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 025 M - -
Net income 2021 5 559 M - -
Net Debt 2021 21 988 M - -
P/E ratio 2021 22,6x
Yield 2021 3,05%
Capitalization 129 B 129 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,47x
Nbr of Employees 24 300
Free-Float -
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 228,90 $
Average target price 238,36 $
Spread / Average Target 4,13%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.1.75%128 932
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
ABBVIE INC.-0.14%239 035
NOVO NORDISK A/S-12.67%223 059